|
| Press Releases |
|
 |
|
| Thursday, August 17, 2023 |
|
|
Asensus Surgical Continues to Spearhead Innovations and Growth in Surgical Robotics |
| Driving towards its goal of continued global growth in the surgical robotics sector, Asensus Surgical (NYSE American: ASXC) provided a positive update on both recent accomplishments and the company's projected outlook for the coming year. more info >> |
|
| Tuesday, June 13, 2023 |
|
|
Lipella Pharmaceuticals: Addressing Significant Unmet Need for Cancer Survivors, Delivering Long Term Value for Shareholders |
| PCG Digital--Lipella Pharmaceuticals (Nasdaq: LIPO) is a clinical-stage biotechnology company addressing serious diseases with significant unmet medical need and potentially changing the lives of countless cancer survivors. more info >> |
|
| Thursday, June 1, 2023 |
|
|
Asensus Shares First Quarter Results and Future Plans |
| PCG Digital -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery(TM), recently shared notable operating and financial results for Q1 2023 and significant plans moving forward. more info >> |
|
| Monday, January 16, 2023 |
|
|
Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024 |
| PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (Nasdaq: SNGX) is on track to deliver a safe and effective front-line treatment to a community of patients living with rare, chronic cancer. more info >> |
|
| Tuesday, August 9, 2022 |
|
|
Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans |
| The development-stage biotech Virios Therapeutics, Inc. (Nasdaq:VIRI) is anticipating the reporting of phase 2b treatment results for its lead fibromyalgia treatment candidate this September and continues to add value through its research and development of compelling clinical assets for multiple categories of viruses. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
維昇藥業（2561.HK）維臻高(R)獲批：重長效生長激素王者登場 重構百億市場的商業天花板
Feb 25, 2026 14:58 HKT/SGT
|
|
|
Hong Kong Tech Delegation Heading for Market Expansion at Mobile World Congress 2026
Feb 25, 2026 14:54 HKT/SGT
|
|
|
CanSinoBIO's Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential
Feb 25, 2026 12:46 HKT/SGT
|
|
|
ベイシアのスーパーマーケット内の冷蔵・冷凍庫の温度点検・記録業務を富士通のIoT可視化ソリューションにより自動化
Feb 25, 2026 12:00: JST
|
|
|
Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu's IoT Visualization Solution
Feb 25, 2026 12:00 JST
|
|
|
國泰君安國際獲批使用SIMM 衍生品風險管理接軌國際標準
Feb 25, 2026 10:34 HKT/SGT
|
|
|
国泰君安国际获批使用SIMM 衍生品风险管理接轨国际标准
Feb 25, 2026 10:34 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 22:30: JST
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 21:30 HKT/SGT
|
|
|
TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines
Feb 24, 2026 22:00 JST
|
|
|
康哲藥業（867.HK/8A8.SG）：創新藥磷酸蘆可替尼乳膏增加特應性皮炎（AD）適應症中國上市許可申請獲受理並獲納入優先審評
Feb 24, 2026 20:31 HKT/SGT
|
|
|
康哲药业（867.HK/8A8.SG）：创新药磷酸芦可替尼乳膏增加特应性皮炎（AD）适应症中国上市许可申请获受理并获纳入优先审评
Feb 24, 2026 20:19 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Ships First Units of Systems for Marine Ammonia-Fueled Engines
Feb 24, 2026 20:07 JST
|
|
|
MHI Unveils "DIAVAULT," a Secure, High Performance Edge Data Center Platform
Feb 24, 2026 19:55 JST
|
|
|
康希諾生物曼海欣(R)擴齡正式獲批 為公司長期價值開啟更廣闊發展空間
Feb 24, 2026 18:15 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
